Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Chemoradiotherapy for Locally Recurrent Rectal Cancer
NCT05628038Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in rectal cancer, sponsored by Fudan University. Primary endpoint: Local objective response rate at 1 year. Started Nov 2022; status: recruiting.
02
Drugs
toripalimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05628038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05628038.